Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06312657 · ClinicalTrials.gov registry record · Early Phase 1
Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice
A Early Phase 1 study, sponsored by Joshua A. Lile, Ph.D..
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT06312657 is a Early Phase 1 study that was terminated before completion, run by Joshua A. Lile, Ph.D.. The registered enrollment target is 2 participants.
The verdict
NCT06312657, a Early Phase 1 study, was terminated before completion, sponsored by Joshua A. Lile, Ph.D..
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The objective of this protocol is to use probabilistic choice tasks to determine the impact of withdrawal and drug cues on decision-making in individuals with opioid use disorder and physical opioid dependence.
Interventions
- DRUG Remifentanil
- BEHAVIORAL Money
- BEHAVIORAL Drug Cue
- DRUG Withdrawal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2025-03-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06312657
The ClinicalTrials.gov registry entry for NCT06312657 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joshua A. Lile, Ph.D., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Remifentanil is the first listed.
NCT06312657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06312657 about?
NCT06312657 is a clinical study titled "Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice". The objective of this protocol is to use probabilistic choice tasks to determine the impact of withdrawal and drug cues on decision-making in individuals with opioid use disorder and physical opioid dependence.
What is the current status of trial NCT06312657?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2023-03-01. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT06312657?
The interventions under investigation include: Remifentanil (DRUG), Money (BEHAVIORAL), Drug Cue (BEHAVIORAL), Withdrawal (DRUG).
Who is sponsoring clinical trial NCT06312657?
This trial is sponsored by Joshua A. Lile, Ph.D., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.